Abstract
Objectives: This three-year, long-term study was intended to
evaluate the incidence of #diabeticmacrovascularevents, micro vascular
events and #hypoglycemicevents after combining sitagliptin with ant #hyperglycemicagents in patients with type 2 #diabetesmellitus.
Methods: This is a retrospective observational study of the
medical records of type 2 diabetes mellitus patients aged 20 years and
older
who had been using sitagliptin, metformin and other concomitant ant
hyperglycemic agents for more than 60 days from January 1, 2009 to
June 30, 2009. All patient medication data were retrieved from the
pharmacy database. The primary outcome was to compare the incidence of
events such as #ischemicstroke, #myocardialinfarction, #peripheralartery occlusive disease, #pulmonaryembolism, diabetic retinopathy, diabetic
nephropathy and severe hypoglycemia in a sitagliptin-based group and a
#metformin-based group.
Results: Over a mean of 3.6 years, there was a 68% reduced
risk of all the adverse events studied in the sitagliptin-based group
compared
to the metformin-based group. The sitagliptin-base group had a reduction
in risk for ischemic stroke, diabetic retinopathy, and diabetic
nephropathy. The subgroup analysis results showed that ORs of incidence
of events in patients younger than age 65 years, female and with
HbA1C less than or equal to 7% after 3 years were significantly lower in
the sitagliptin-base group.
For more Biomedical open access journals please click on
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.